David Jacoby, M.D., Ph.D., joined 澳门正规博彩十大排行平台 in 2012 and currently serves as 澳门正规博彩十大排行平台 Fellow in Clinical Science and Vice President, Head of Discovery Medicine. In these roles, Dr. Jacoby leads efforts to identify and evaluate potential clinical indications and technical platforms for early stage development at 澳门正规博彩十大排行平台. He previously served as Head of Clinical Sciences at 澳门正规博彩十大排行平台, where he was responsible for development stage programs for hemophilia A, achondroplasia, PKU and CLN2 disease and supported decision-making for non-progressed programs.
Before joining 澳门正规博彩十大排行平台, Dr. Jacoby spent eight years at Repligen Corporation, where he was involved in programs for spinal muscular atrophy (SMA), Friedreich’s Ataxia, autism, bipolar depression and imaging in pancreatitis.
Dr. Jacoby is a neurologist trained at Massachusetts General Hospital and Harvard University, with fellowships in movement disorders and molecular neurogenetics. He earned a B.A. degree in liberal arts from Swarthmore College and both an M.D. and a Ph.D. in molecular biology from the University of Pennsylvania.
Dr. Jacoby has authored 30 peer-reviewed articles. In addition, he has been a member of National Institute of Neurological Disorders and Stroke (NINDS) Study Sections on Friedreich’s ataxia and Rare Disease Clinical Trial Preparedness.
We maximize the impact of genetic innovation to develop transformative therapies.
Each drug candidate we pursue is guided by a fundamental understanding of the genetics and underlying biology of the condition it will address.
Learn More Our Pipeline ⌃